ALLMedicine Heart Failure Center

May 29th, 2020 - Effective tacrolimus (TAC) dosing is hampered by complex pharmacokinetics and significant patient variability. The gut microbiome, a key mediator of endotoxemia, inflammation and oxidative stress in advanced heart failure (HF) patients, is a possi...

May 29th, 2020 - Entresto® (sacubitril/valsartan) is used to treat symptomatic chronic heart failure with reduced ejection fraction. Given its high potential budget impact, the Health Services Executive introduced a reimbursement application system (RAS) to ensure...

May 28th, 2020 - We investigated the performance of four prognostic tools in predicting 180-day mortality for patients admitted for decompensated heart failure (ADHF) by calculating sensitivity, specificity, positive predictive value (PPV), and negative predictive...

May 28th, 2020 - Indoxyl sulfate (IS) is a protein-bound uremic toxin that can accumulate in patients with chronic kidney disease (CKD) or acute kidney injury (AKI) and cause kidney and cardiac dysfunction. Klotho is an anti-aging protein that has reno- and cardio...

May 28th, 2020 - Rationale: Doxorubicin-induced cardiomyopathy (DiCM) is a primary cause of heart failure and mortality in cancer patients, in which macrophage-orchestrated inflammation serves as an essential pathological mechanism. However, the specific roles of ...

Apr 1st, 2020 - The latest news from the ACC Annual Scientific Session, with physician perspective, researcher interviews and clinician insight on cardiovascular prevention, heart failure and more.

Mar 16th, 2020 - As the global impact of COVID-19 rises, the scientific community continues to evaluate the clinical impact and health care needs of patients with cardiovascular disease, who are at increased risk for serious complications with COVID-19. Together, ...

Feb 22nd, 2020 - 2020 ACC/HFSA/ISHLT Lifelong Learning Statement for Advanced Heart Failure and Transplant Cardiology Specialists: A Report of the ACC Competency Management Committee.|2020|Yancy CW,Drazner MH,Coffin ST,Cornwell W,Desai S,|

Feb 22nd, 2020 - 2020 ACC/HFSA/ISHLT Lifelong Learning Statement for Advanced Heart Failure and Transplant Cardiology Specialists: A Report of the ACC Competency Management Committee.|2020| ,Yancy CW,Drazner MH,Coffin ST,Cornwell W,|

Feb 9th, 2020 - In this update, we focus on selected topics of high clinical relevance for health care providers who treat patients with heart failure (HF), on the basis of clinical trials published after 2017. Our objective was to review the evidence, and provid...

May 29th, 2020 - Effective tacrolimus (TAC) dosing is hampered by complex pharmacokinetics and significant patient variability. The gut microbiome, a key mediator of endotoxemia, inflammation and oxidative stress in advanced heart failure (HF) patients, is a possi...

May 29th, 2020 - Entresto® (sacubitril/valsartan) is used to treat symptomatic chronic heart failure with reduced ejection fraction. Given its high potential budget impact, the Health Services Executive introduced a reimbursement application system (RAS) to ensure...

May 28th, 2020 - We investigated the performance of four prognostic tools in predicting 180-day mortality for patients admitted for decompensated heart failure (ADHF) by calculating sensitivity, specificity, positive predictive value (PPV), and negative predictive...

May 28th, 2020 - Indoxyl sulfate (IS) is a protein-bound uremic toxin that can accumulate in patients with chronic kidney disease (CKD) or acute kidney injury (AKI) and cause kidney and cardiac dysfunction. Klotho is an anti-aging protein that has reno- and cardio...

May 28th, 2020 - Rationale: Doxorubicin-induced cardiomyopathy (DiCM) is a primary cause of heart failure and mortality in cancer patients, in which macrophage-orchestrated inflammation serves as an essential pathological mechanism. However, the specific roles of ...

May 27th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. An elderly man with congestive heart failure was getting worse, but fear of going to the emergency department during the COVID-19 public health cr...

May 27th, 2020 - Heart failure (HF), a common complication of myocardial infarction (MI), occurs in 14%-36% of hospitalized patients. Patients with HF can present with a wide spectrum of clinical severity, ranging from asymptomatic left ventricular (LV) dysfunctio...

May 21st, 2020 - Related News Stories VICTORIA: Vericiguat Seen as Novel Success in Tough-to-Treat, High-Risk Heart Failure Rivaroxaban Plus Aspirin Safely Benefits PAD Patients After Limb Revascularization REDUCE-IT: CV Benefit of Icosapent Ethyl Directly Related...

May 19th, 2020 - Autologous CD34-positive stem cells may improve coronary flow reserve and angina symptoms in patients with microvascular dysfunction, proof-of-concept testing suggests. Evidence of microvascular dysfunction is present in about 50% to 70% of patien...

May 14th, 2020 - NEW YORK (Reuters Health) — According to projections from a decision-analytical model, sodium-glucose co-transporter 2 (SGLT2) inhibitor therapy could be of great benefit in certain patients with heart failure. The findings show "that the addition...